MedTrace Logo

Clinical Study of 12-week Trehalose Intake in Patients With Fatty Liver Disease

NCT03738358 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2019-01-30

No results posted yet for this study

Summary

This clinical study will be conducted to evaluate the efficacy and safety of trehalose in patients with fatty liver disease. After 12-week intake, subjects will be checked up fat content in liver using CT scan.

Conditions

  • Non-alcoholic Fatty Liver

Interventions

DIETARY_SUPPLEMENT

Trehalose

80 mL pouch/day for 12 weeks, containing trehalose 5 g, water 74.92 g and scent additive 0.08 g

OTHER

Placebo

80 mL pouch/day for 12 weeks, containing water 79.92 g and scent additive 0.08 g

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-03-20
Completion
2018-03-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03738358 on ClinicalTrials.gov